Powered by
Acerus Reports Fourth Quarter and Full Year 2016 Financial Results

Acerus Pharmaceuticals Corporation (TSX:ASP) today reported its financial results for the three and twelve-month period ended December 31, 2016. Unless otherwise noted, all amounts are in U.S. dollars.

"Despite the introduction of an Estrace® generic, Acerus managed to deliver strong financial results for the year and significantly strengthened its balance sheet," said Tom Rossi, President and Chief Executive Officer. "We are very excited about the new Natesto® partners we have brought o

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox